» Articles » PMID: 15129893

Gastroparesis Cardinal Symptom Index (GCSI): Development and Validation of a Patient Reported Assessment of Severity of Gastroparesis Symptoms

Overview
Journal Qual Life Res
Date 2004 May 8
PMID 15129893
Citations 138
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patient-rated symptom assessments are needed for evaluating the effectiveness of medical treatments and for monitoring outcomes in gastroparesis.

Objective: This paper summarizes the development and psychometric evaluation of a new instrument, the Gastroparesis Cardinal Symptom Index (GCSI), for assessing severity of symptoms associated with gastroparesis.

Methods: The GCSI was based on reviews of the medical literature, patient focus groups, and interviews with clinicians. A sample of 169 patients with a documented diagnosis of gastroparesis participated in the psychometric evaluation study. Patients completed the GCSI, the SF-36 Health Survey, and disability days questions at baseline and after 8 weeks. A randomly selected sub-sample of 30 subjects returned at 2 weeks to assess test retest reliability. Clinicians rated severity of symptoms, and both clinicians and patients rated change in gastroparesis-related symptoms over the 8 week study.

Results: The GCSI is based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). Internal consistency reliability was 0.84 for the GCSI total score and ranged from 0.83 to 0.85 for the subscale scores. Two week test retest reliability was 0.76 for the total score and ranged from 0.68 to 0.81 for subscale scores. Construct validity was supported, given that we observed significant relationships between clinician assessed symptom severity and GCSI total score, significant differences between gastroparesis and dyspepsia patients (n = 760) on GCSI total (p < 0.0001) and subscale scores (p < 0.03 to p < 0.0001), moderate and significant relationships between GCSI total and SF-36 scores, and significant associations between GCSI total score and reports of restricted activity and bed disability days. Patients with greater symptom severity, as rated by clinicians, reported more symptom severity on GCSI total score. GSCI total scores were responsive to changes in overall gastroparesis symptoms as assessed by clinicians (p < 0.0001) and patients (p = 0.0004).

Conclusion: The findings of this study indicate that the GCSI is a reliable and valid instrument for measuring symptom severity in patients with gastroparesis.

Citing Articles

Impact of distal or pylorus preserving gastrectomy on postoperative quality of life in T1 stage middle third gastric cancer patients.

Chen H, Jing S, Li Z, Cao L, Guan W, Chen X Sci Rep. 2025; 15(1):8632.

PMID: 40082480 PMC: 11906802. DOI: 10.1038/s41598-025-90866-8.


Prevalence of gastroparesis symptoms and its associated factors among type 2 diabetes mellitus patients in West Bank in Palestine: a national cross-sectional study.

Asad D, Zreqat Q, Idais S, Hussein B, Ayyad A, Hunjul M Front Med (Lausanne). 2025; 12:1499725.

PMID: 40012984 PMC: 11862999. DOI: 10.3389/fmed.2025.1499725.


Diabetic gastroenteropathy: a pan-alimentary complication.

Kornum D, Krogh K, Keller J, Malagelada C, Drewes A, Brock C Diabetologia. 2025; .

PMID: 39934370 DOI: 10.1007/s00125-025-06365-y.


Novel brain SPECT imaging unravels abnormal cerebral perfusion in patients with postural orthostatic tachycardia syndrome and cognitive dysfunction.

Seeley M, OBrien H, Wilson G, Coat C, Smith T, Hickson K Sci Rep. 2025; 15(1):3487.

PMID: 39875497 PMC: 11775248. DOI: 10.1038/s41598-025-87748-4.


A Standardized Classification Scheme for Gastroduodenal Disorder Evaluation Using the Gastric Alimetry System: Prospective Cohort Study.

Varghese C, Schamberg G, Uren E, Calder S, Law M, Foong D Gastro Hep Adv. 2025; 4(1):100547.

PMID: 39802489 PMC: 11719321. DOI: 10.1016/j.gastha.2024.09.002.


References
1.
Jones K, Wishart J, Berry M, Abitbol J, Horowitz M . Effects of fedotozine on gastric emptying and upper gastrointestinal symptoms in diabetic gastroparesis. Aliment Pharmacol Ther. 2000; 14(7):937-43. DOI: 10.1046/j.1365-2036.2000.00790.x. View

2.
Horowitz M, Wishart J, Jones K, Hebbard G . Gastric emptying in diabetes: an overview. Diabet Med. 1996; 13(9 Suppl 5):S16-22. View

3.
Rentz A, Battista C, Trudeau E, Jones R, Robinson P, Sloan S . Symptom and health-related quality-of-life measures for use in selected gastrointestinal disease studies: a review and synthesis of the literature. Pharmacoeconomics. 2001; 19(4):349-63. DOI: 10.2165/00019053-200119040-00003. View

4.
Soykan I, Sarosiek I, McCallum R . The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol. 1997; 92(6):976-80. View

5.
Farup C, Leidy N, Murray M, Williams G, Helbers L, Quigley E . Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care. 1998; 21(10):1699-706. DOI: 10.2337/diacare.21.10.1699. View